ABIVAX Société Anonyme (ABVX) Stock Overview

A clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. More details

ABVX fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Earnings are forecast to grow 64.11% per year

Risk Analysis

Highly volatile share price over the past 3 months compared to the French market

Shareholders have been diluted in the past year

ABVX Community Fair Values

Create Narrative

See what 20 others think this stock is worth. Follow their fair value or set your own to get alerts.

Top Community Narratives

ABIVAX Société Anonyme

54.0% undervalued

OBE is best in disease

Polip

Published 3 Jul

Read Narrative

Top Community Narratives

ABIVAX Société Anonyme

54.0% undervalued

OBE is best in disease

Polip

Published 3 Jul

Read Narrative

View all narratives

ABIVAX Société Anonyme Competitors

Price History & Performance

Summary of share price highs, lows and changes for ABIVAX Société Anonyme
Historical stock prices
Current Share Price	€101.30
52 Week High	€139.00
52 Week Low	€60.45
Beta	-0.25
1 Month Change	-7.32%
3 Month Change	19.11%
1 Year Change	43.28%
3 Year Change	516.18%
5 Year Change	220.57%
Change since IPO	382.38%

Recent updates

New Narrative • Jul 03

OBE is best in disease

In my opinion, Abivax is worth much more than its current share price of around €136. The market still seems to value the company as if there is a lot of uncertainty, but I believe much of that uncertainty has now been reduced.

Shareholder Returns

	ABVX	FR Biotechs	FR Market
7D	3.8%	-0.007%	-2.3%
1Y	43.3%	25.6%	-1.1%

Return vs Industry: ABVX exceeded the French Biotechs industry which returned 25.6% over the past year.

Return vs Market: ABVX exceeded the French Market which returned -1.1% over the past year.

Price Volatility

Is ABVX's price volatile compared to industry and market?
ABVX volatility
ABVX Average Weekly Movement	12.2%
Biotechs Industry Average Movement	7.0%
Market Average Movement	4.2%
10% most volatile stocks in FR Market	9.3%
10% least volatile stocks in FR Market	2.2%

Stable Share Price: ABVX's share price has been volatile over the past 3 months compared to the French market.

Volatility Over Time: ABVX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

Founded	Employees	CEO	Website
2013	80	Marc M. de Garidel	www.abivax.com

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.

ABIVAX Société Anonyme Fundamentals Summary

How do ABIVAX Société Anonyme's earnings and revenue compare to its market cap?
ABVX fundamental statistics
Market cap	€8.74b
Earnings (TTM)	-€332.20m
Revenue (TTM)	€4.92m

1,795x

P/S Ratio

-26.6x

P/E Ratio

Is ABVX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ABVX income statement (TTM)
Revenue	€4.92m
Cost of Revenue	€0
Gross Profit	€4.92m
Other Expenses	€337.12m
Earnings	-€332.20m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

Sep 21, 2026

Earnings per share (EPS)	-3.81
Gross Margin	100.00%
Net Profit Margin	-6,752.03%
Debt/Equity Ratio	7.6%

How did ABVX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/11 18:07
End of Day Share Price	2026/09/11 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ABIVAX Société Anonyme is covered by 22 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Etzer Darout	Barclays
Julian Harrison	BTIG
Jason Butler	Citizens JMP Securities, LLC

ABIVAX Société Anonyme (ABVX) Stock Overview

Rewards

Risk Analysis

Top Community Narratives

OBE is best in disease

Top Community Narratives

OBE is best in disease

ABIVAX Société Anonyme Competitors

Valerio Therapeutics Société anonyme

DBV Technologies

Valneva

Eurobio Scientific Société anonyme

Price History & Performance

Recent News & Updates

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Abivax Announces Positive Pre-NDA Interaction With FDA For Obefazimod

Abivax Adds Senior Executives to Advance US Launch Preparation for Obefazimod

Abivax SA Announces Executive Appointments

Valerio Therapeutics Enters into Binding Term-Sheet with Abivax for Exclusive Global Research and Development Collaboration and Provides Pipeline Update

Recent updates

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Abivax Announces Positive Pre-NDA Interaction With FDA For Obefazimod

Abivax Adds Senior Executives to Advance US Launch Preparation for Obefazimod

Abivax SA Announces Executive Appointments

Valerio Therapeutics Enters into Binding Term-Sheet with Abivax for Exclusive Global Research and Development Collaboration and Provides Pipeline Update

New major risk - Shareholder dilution

ABIVAX Société Anonyme has completed a Follow-on Equity Offering in the amount of $800 million.

OBE is best in disease

ABIVAX Société Anonyme has filed a Follow-on Equity Offering in the amount of $600 million.

Consensus revenue estimates increase by 1,892%

Abivax Raises $800 Million in Oversubscribed US Offering to Extend Cash Runway

Price target increased by 11% to €120

Abivax Reports Positive Abtect Maintenance Part 2 Results for Obefazimod in Refractory Ulcerative Colitis Patients

Price target decreased by 7.6% to €106

Abivax Stock Rises on Positive Phase 3 Obefazimod Results and Strong Cash Position Through 2027

Consensus EPS estimates fall by 13%

No longer forecast to breakeven

Abivax Reports Landmark Phase 3 Abtect Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis

Now 53% undervalued after recent price drop

Abivax’s Ulcerative Colitis Trial Hits Remission Targets as Cancer Risks Raise Investor Caution

Consensus revenue estimates increase by 25%

Forecast to breakeven in 2028

New minor risk - Share price stability

Consensus revenue estimates fall by 16%

New minor risk - Profitability

Forecast to breakeven in 2028

ABIVAX Société Anonyme, Annual General Meeting, May 11, 2026

ABIVAX Société Anonyme Announces Board and Management Changes

Forecast to breakeven in 2028

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease At Ecco 2026

Price target increased by 17% to €109

Consensus revenue estimates increase by 45%

Consensus revenue estimates increase by 48%

ABIVAX Société Anonyme to Report First Half, 2026 Results on Sep 14, 2026

ABIVAX Société Anonyme to Report Fiscal Year 2025 Results on Mar 23, 2026

New major risk - Share price stability

Consensus revenue estimates increase by 16%, EPS downgraded

Abivax SA Presents 22 Abstracts On Obefazimod In Inflammatory Bowel Disease At ECCO 2026 Including Oral Presentation On Preclinical Anti-Fibrotic Findings

Abivax SA Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies

Consensus revenue estimates increase by 170%

New minor risk - Shareholder dilution

Price target increased by 43% to €34.13

ABIVAX Société Anonyme has completed a Follow-on Equity Offering in the amount of $649.984 million.

ABIVAX Société Anonyme has filed a Follow-on Equity Offering in the amount of $400 million.

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, Its First-In-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis

Consensus revenue estimates decrease by 59%

New major risk - Negative shareholders equity

Abivax Sa Announces Completion of Enrollment for the Phase 3 Abtect Trials in Patients with Moderately to Severely Active Ulcerative Colitis

Abivax SA Appoints Dominik Höchli to the Board of Directors

Consensus revenue estimates increase by 24%, EPS downgraded

New major risk - Financial position

New major risk - Share price stability

ABIVAX Société Anonyme, Annual General Meeting, Jun 06, 2025

ABIVAX Société Anonyme to Report Q1, 2025 Results on Jun 02, 2025

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment

New minor risk - Share price stability

Abivax SA Announces Resignation of Philippe Pouletty as Director, Effective December 31, 2024

ABIVAX Société Anonyme has filed a Follow-on Equity Offering in the amount of €150 million.